Filing Date |
T Date |
Ticker |
Sector |
Ind | Industry |
Owner |
oSt |
Rel |
Title |
#f |
T |
TVal |
Price |
L |
Qty |
oc |
Own |
H |
r2y |
r1y |
r6m |
r3m |
r6w |
r3w |
r7d |
r3d |
f1d |
f1w |
f1m |
f3m |
f6m |
f1y |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
7/9/26 18:04 | 7/7/26 | RXRX | Health | BioPrd | Biological Products, (No Diag | Borgeson Blake | UT | D | 8 | S | -3,900 | 4.06 | 0 | -960 | 6,870 | D | ||||||||||||||||
6/22/26 16:32 | 6/3/26 | RXRX | Health | BioPrd | Biological Products, (No Diag | Bumpus Namandje | UT | D | 2 | S | -28 | 3.37 | 0 | -8 | 128 | D | ||||||||||||||||
6/5/26 17:03 | 6/5/26 | RXRX | Health | BioPrd | Biological Products, (No Diag | Gibson Christopher | UT | D | 22 | S.dm | -9,158 | 4.93 | 0 | -1,857 | 1,256 | D | ||||||||||||||||
6/5/26 17:02 | 6/5/26 | RXRX | Health | BioPrd | Biological Products, (No Diag | Khan Najat | UT | DO | CEO,P | 4 | S.d | -930 | 4.37 | 0 | -213 | 2,262 | D | |||||||||||||||
3/18/26 17:52 | 3/17/26 | RXRX | Health | BioPrd | Biological Products, (No Diag | Taylor Ben R | UT | O | CFO | 3 | S | -158 | 3.69 | 0 | -43 | 1,195 | D |
| D | Derivative transaction in filing (usually option exercise) |
| M | Multiple transactions in filing; earliest reported transaction date and weighted average transaction price |
| A | Amended filing |
| E | Error detected in filing |
| S - Sale | Sale of securities on an exchange or to another person |
| S - Sale+OE | Sale of securities on an exchange or to another person (after option exercise) |
| F - Tax | Payment of exercise price or tax liability using portion of securities received from the company |
| P - Purchase | Purchase of securities on an exchange or from another person |